Physician profile
Mohammad A Ansari
NPI 1891874863
$2,533.41
in general payments reported to CMS, 2019-2025
16 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $505 · 2021: $190 · 2022: $466 · 2023: $332 · 2024: $449 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.91 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $618.89 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $487.92 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $285.10 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Integra Lifesciences Corporation | $226.55 | 2020 | |
| Sunovion Pharmaceuticals INC. | $169.77 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $143.26 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $124.98 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $75.80 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $75.61 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $72.27 | 2019-2025 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $69.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.27 | 2024-2025 | Cobenfy |
| Allergan, INC. | $45.50 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.73 | 2024 | Caplyta |
| Indivior INC. | $21.47 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.76 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.